Investor Highlights | Medtronic


This site uses cookies to store information on your computer. Some are essential to make our site work; others help us improve the user experience. By using the site, you consent to the placement of these cookies. You may at any time change the settings regarding cookies. Read our privacy statement to learn more.

Privacy Statement

Key Investor Highlights

Investor highlights regarding Medtronic’s acquisition of Covidien

The combination of Medtronic and Covidien creates a medical technology and services company with a comprehensive product portfolio, a diversified growth profile and broad geographic reach.


Therapy innovation

With its expanded portfolio of innovative products and services, Medtronic is a preeminent leader in delivering therapy and procedural innovations to address the major disease states impacting patients and healthcare costs around the world. Covidien has an impressive portfolio of industry-leading products that enhance Medtronic’s existing portfolio, offer greater breadth across clinical areas, or create exciting entry points into new therapies.



With a presence in more than 150 countries, the combined entity will be better able to serve global market needs. Medtronic and Covidien have combined revenues of $13 billion from outside the U.S., of which $3.7 billion comes from emerging markets. Covidien’s extensive capabilities in emerging market R&D and manufacturing, joined with Medtronic’s demonstrated clinical expertise across a much broader product offering, significantly increases the number of attractive solutions the new company is able to offer to governments, major providers, and physicians globally.


Economic value

With Covidien, Medtronic is able to provide a broader array of complementary technologies and solutions that can be packaged to drive more value and efficiency in healthcare systems. Both companies’ deep relationships with healthcare system stakeholders provide enormous ability to identify and create further value-based solutions.


The transaction creates significant benefits for both Medtronic and Covidien shareholders.